CRMD logo

CRMD
CorMedix Inc

22,631
Loading...
Loading...
News
all
press releases
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
Zacks·4d ago
News Placeholder
More News
News Placeholder
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
Zacks·5d ago
News Placeholder
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Zacks·5d ago
News Placeholder
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
Zacks·12d ago
News Placeholder
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Zacks·13d ago
News Placeholder
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
Zacks·16d ago
News Placeholder
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
Zacks·16d ago
News Placeholder
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
Zacks·23d ago
News Placeholder
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
Zacks·24d ago
News Placeholder
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Zacks·24d ago

Latest CRMD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.